Advances in PSMA-Targeted Radionuclide Therapeutics

Area of Science:

• Oncology
• Nuclear Medicine
• Radiopharmaceutical Therapy

Background:

• Prostate-specific membrane antigen targeted radionuclide therapies (PSMA-TRT) offer new hope for prostate cancer treatment.
• 177Lu-PSMA-617 is FDA-approved for metastatic castration-resistant prostate cancer (mCRPC), marking a significant therapeutic advance.

Purpose of the Study:

• To review the current state and future directions of PSMA-TRT in prostate cancer management.
• To highlight the potential of 177Lu-PSMA-617 in various disease stages and treatment combinations.

Main Methods:

• Review of clinical trial data, including the VISION and PSMAfore trials.
• Discussion of emerging radionuclides and delivery vehicles for PSMA-TRT.
• Exploration of combination therapies and predictive biomarkers.

Main Results:

• 177Lu-PSMA-617 demonstrated improved radiographic progression-free survival (rPFS) and overall survival (OS) in mCRPC patients post-ARPI and taxane therapy.
• Early-stage application and combination strategies are under active investigation with promising preliminary findings.

Conclusions:

• PSMA-TRT, particularly 177Lu-PSMA-617, is a rapidly evolving field with the potential to significantly improve prostate cancer outcomes.
• Future research focusing on predictive biomarkers, dosimetry, and novel therapeutic combinations will be key to optimizing PSMA-TRT's role in prostate cancer care.